Dry Eye – Landscape & Forecast – Disease Landscape & Forecast
Dry eye disease (DED) is a chronic, inflammatory, and highly heterogeneous condition of the eye; it is also referred to as dry eye syndrome or keratoconjunctivitis sicca. Although DED represents a large prevalent pool in the G7 markets, the condition is underdiagnosed and few drugs are approved to treat it. As such, commercial opportunity abounds in this space. Indeed, despite the challenges in drug development for DED, the pipeline is robust, with a number of drugs in active late-phase development. With the expected launch of six new drugs for DED and the generic entry of AbbVie’s blockbuster Restasis in the United States, the DED therapy market is set to be dynamic and competitive over the next decade.
QUESTIONS ANSWERED
- How large is the prescription drug-treatable DED population in the G7 countries? How will drug-treatment rates change over the 2019-2029 forecast period?
- What is the current size of the DED market for key prescription therapies in the G7 countries? How will key events, including the generic availability of Restasis in the United States, influence the market over the next decade?
- What is the current state of DED treatment? Which are the most important prescription drug classes / drugs and why? What are interviewed experts’ insights on current treatment options?
- What are the biggest areas of unmet need? Which late-phase therapies have the potential to fulfill these needs? What therapies of note are progressing in earlier phases?
CONTENT HIGHLIGHTS
Geographies: United States, EU5, Japan.
Primary research: 20 country-specific interviews with thought-leading ophthalmologists and optometrists. Supported by survey data collected for this and other DRG research.
Epidemiology: Total prevalence of DED by country, including diagnosed prevalence and prescription drug-treatment rates.
Forecast: 10-year, annualized, drug-level sales and patient share of key therapies for DED through 2029, segmented by brands / generics.
Emerging therapies: Phase III: 7 drugs; coverage of select Phase II drugs.
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Table of contents
- Dry Eye - Landscape & Forecast - Disease Landscape & Forecast
- COVID-19
- Key Findings
- Dry Eye Disease Key Findings - December 2020
- Key Updates
- December 2020
- August 2020
- December 2020
- Market Outlook
- Key Findings
- Market Share of Drug Classes for Dry Eye Disease: 2019
- Market Share of Drug Classes for Dry Eye Disease: 2029
- Dry Eye Disease SWOT Analysis
- COVID-19: Areas of Potential Forecast Impact
- Market Drivers and Constraints
- What Factors Are Driving the Market for Dry Eye Disease?
- What Factors Are Constraining the Market for Dry Eye Disease?
- Market Share and Share of Treated Patients for Dry Eye Disease by Region: 2019 and 2029
- Major-Market Sales and Overall Drug-Treated Patients in Dry Eye Disease: 2019-2029
- Major-Market Brand and Generic Sales in Dry Eye Disease: 2019-2029
- Major-Market Brand and Generic Patient Share in Dry Eye Disease: 2019-2029
- Drug-Class-Specific Trends
- Major-Market Sales of Calcineurin Inhibitors (Ophthalmic) in Dry Eye Disease: 2019-2029
- Patient Share of Calcineurin Inhibitors (Ophthalmic) in Dry Eye Disease in the United States: 2019-2029
- Treated Patients and Overall Patient Share of Calcineurin Inhibitors (Ophthalmic) in Dry Eye Disease in the United States: 2019-2029
- Treated Patients and Patient Share of Cyclosporine Ophthalmic Emulsion, 0.1% (Ikervis) in Dry Eye Disease in the EU5: 2019-2029
- Major-Market Sales of Lifitegrast Ophthalmic Solution, 5% (Xiidra) in Dry Eye Disease: 2019-2029
- Treated Patients and Patient Share of Lifitegrast Ophthalmic Solution, 5% (Xiidra) in Dry Eye Disease in the United States: 2019-2029
- Major-Market Sales of Secretagogues in Dry Eye Disease: 2019-2029
- Patient Share of Secretagogues in Dry Eye Disease in Japan: 2019-2029
- Major-Market Sales of Corticosteroids (Ophthalmic) in Dry Eye Disease: 2019-2029
- Patient Share of Corticosteroids (Ophthalmic) in Dry Eye Disease in the United States: 2019-2029
- Patient Share of Corticosteroids (Ophthalmic) in Dry Eye Disease in the EU5: 2019-2029
- Patient Share of Corticosteroids (Ophthalmic) in Dry Eye Disease in Japan: 2019-2029
- Treated Patients and Overall Patient Share of Corticosteroids (Ophthalmic) in Dry Eye Disease in the United States: 2019-2029
- Sales and Patient Share of Varenicline Nasal Spray (OC-01) in Dry Eye Disease in the United States: 2019-2029
- Sales and Patient Share of Reproxalap (ADX-102) in Dry Eye Disease in the United States: 2019-2029
- Sales and Patient Share of Timbetasin (RGN-259) in Dry Eye Disease in the United States: 2019-2029
- Sales and Patient Share of NOV03 in Dry Eye Disease in the United States: 2019-2029
- Key Findings
- Forecast
- Market Forecast Assumptions
- Market Forecast Dashboard
- Etiology and Pathophysiology
- Disease Overview
- Etiology
- Risk Factors for Dry Eye Disease
- Nonmodifiable and Modifiable Risk Factors for Dry Eye Disease
- Details of Consistentu00a0Risk Factors for Dry Eye Disease
- Classification of Dry Eye Disease
- Etiological Classification of Dry Eye Disease
- Pathophysiology
- Vicious Cycle of Dry Eye Disease
- Lacrimal Functional Unit and Key Pathologic Changes in Dry Eye Disease
- Key Pathways and Drug Targets
- Potential Drug Targets for Dry Eye Disease
- Disease Overview
- Epidemiology
- Key Findings
- Epidemiology Populations
- Disease Definition
- Methods
- Sources Used for Total Prevalence of Dry Eye Disease
- Total Prevalent Cases of Dry Eye Disease: 2019-2029 (in thousands)
- Disease Definition
- Methods
- Sources Used for Diagnosed Prevalence of Dry Eye Disease
- Diagnosed Prevalent Cases of Dry Eye Disease: 2019-2029 (in thousands)
- Drug-Treated Diagnosed Prevalent Cases of Dry Eye Disease: 2019-2029 (in thousands)
- Key Findings
- Current Treatment
- Key Findings
- Treatment Goals
- Key Endpoints Used in Clinical Trials for Dry Eye Disease
- Key Current Therapies
- Overview
- Mechanism of Action of Key Current Drug Classes Used for Dry Eye Disease
- Select Current Drugs Used for Dry Eye Disease
- Market Events Impacting the Use of Key Current Therapies for DED
- Advantages and Disadvantages of Restasis / Restasis MultiDose
- Expert Insight: Restasis / Restasis MultiDose
- Advantages and Disadvantages of Cequa
- Expert Insight: Cequa
- Advantages and Disadvantages of Ikervis
- Expert Insight: Ikervis
- Advantages and Disadvantages of Xiidra
- Expert Insight: Xiidra
- Advantages and Disadvantages of Diquas
- Expert Insight: Diquas
- Advantages and Disadvantages of Mucosta Ophthalmic
- Expert Insight: Mucosta Ophthalmic
- Potential Advantages and Disadvantages of Eysuvis
- Expert Insight: Eysuvis
- Medical Practice
- Overview
- Country-Specific Dry Eye Disease Treatment Guidelines
- Factors Influencing Drug Selection in Dry Eye Disease
- Treatment Decision Tree for Dry Eye Disease: United States
- Treatment Decision Tree for Dry Eye Disease: Europe
- Treatment Decision Tree for Dry Eye Disease: Japan
- Key Findings
- Unmet Need Overview
- Current and Future Attainment of Unmet Needs in Dry Eye Disease
- Top Unmet Needs in Dry Eye Disease: Current and Future Attainment
- Expert Insight: Unmet Need in Dry Eye Disease
- Emerging Therapies
- Key Findings
- Pipeline Trends in Dry Eye Disease
- Key Emerging Therapies
- Key Therapies in Development for Dry Eye Disease
- Estimated Launch Dates of Key Emerging Therapies for the Treatment of Dry Eye Disease
- NOV03 Profile
- Analysis of the Clinical Development Program for NOV03
- Expert Insight: NOV03
- Expectations for Launch and Sales Opportunity of NOV03 in Dry Eye Disease
- Key Development Milestones for NOV03 in the Treatment of Dry Eye Disease
- Likely Uses of NOV03 for the Treatment of Dry Eye Disease
- OC-01 Profile
- Analysis of the Clinical Development Program for OC-01
- Expert Insight: OC-01
- Expectations for Launch and Sales Opportunity of OC-01 in Dry Eye Disease
- Key Development Milestones for OC-01 in the Treatment of Dry Eye Disease
- Likely Uses of OC-01 for the Treatment of Dry Eye Disease
- Reproxalap Profile
- Analysis of the Clinical Development Program for Reproxalap
- Expectations for Launch and Sales Opportunity of Reproxalap in Dry Eye Disease
- Key Development Milestones for Reproxalap in the Treatment of Dry Eye Disease
- Likely Uses of Reproxalap for the Treatment of Dry Eye Disease
- RGN-259 Profile
- Analysis of the Clinical Development Program for RGN-259
- Expectations for Launch and Sales Opportunity of RGN-259 in Dry Eye Disease
- Key Development Milestones for RGN-259 in the Treatment of Dry Eye Disease
- Likely Uses of RGN-259 for the Treatment of Dry Eye Disease
- CyclASol Profile
- Analysis of the Clinical Development Program for CyclASol
- Expectations for Launch and Sales Opportunity of CyclASol in Dry Eye Disease
- Key Development Milestones for CyclASol in the Treatment of Dry Eye Disease
- Likely Uses of CyclASol for the Treatment of Dry Eye Disease
- Tavilermide Profile
- Analysis of the Clinical Development Program for Tavilermide
- Expectations for Launch and Sales Opportunity of Tavilermide in Dry Eye Disease
- SkQ1 Profile
- Analysis of the Clinical Development Program for SkQ1
- Expectations for Launch and Sales Opportunity of SkQ1 in Dry Eye Disease
- Key Development Milestones for SkQ1 in the Treatment of Dry Eye Disease
- Likely Uses of SkQ1 for the Treatment of Dry Eye Disease
- Early-Phase Pipeline Analysis
- Select Compounds in Phase II Development for Dry Eye Disease
- Key Discontinuations and Failures in Dry Eye Disease
- Key Discontinuations and Failures
- Key Findings
- Access & Reimbursement Overview
- Region-Specific Reimbursement Practices
- Key Market Access Considerations in Dry Eye Disease: United States
- General Reimbursement Environment: United States
- Key Market Access Considerations in Dry Eye Disease: EU5
- General Reimbursement Environment: EU5
- Key Market Access Considerations in Dry Eye Disease: Japan
- General Reimbursement Environment: Japan
- Looking for More?
- Region-Specific Reimbursement Practices
- Appendix
- Key Abbreviations Related to Dry Eye Disease
- Brands, Marketers, and Generic Availability of Key Therapies for Dry Eye Disease: by Market
- Dry Eye Disease Bibliography
- COVID-19
Himanshu Jain, M.S.(Pharm.), is a manager on the CNS/Ophthalmology Disorders team at Clarivate. He has authored content for ophthalmology (retinal / nonretinal) and psychiatry indications, including age-related macular degeneration, diabetic retinopathy / diabetic macular edema, glaucoma, uveitis, and schizophrenia. He has more than ten years of experience working in market research and consulting firms. He earned his master’s degree from the National Institute of Pharmacological Education and Research and holds an Executive Post-Graduate Diploma in international business from the Indian Institute of Foreign Trade.
Emma McFadden, Ph.D., is a director on the CNS/Ophthalmology Disorders team at Clarivate. Her focus is on ophthalmic indications, such as age-related macular degeneration, diabetic retinopathy, and diabetic macular edema, although she has authored reports in a number of other indications, including multiple sclerosis and epilepsy. Dr. McFadden earned a B.A. in neuroscience and a Ph.D. in biochemistry from Trinity College in Dublin.
Fjoralba Kristo, M.D., M.P.H., is an epidemiologist at DRG, part of Clarivate. Prior to joining DRG, she completed a postdoctoral fellowship at the University of Kentucky, Division of Cardiovascular Medicine, and more recently worked as a research scientist at Massachusetts General Hospital, where she investigated mechanisms of inflammation in cardiovascular diseases. Dr. Kristo holds an M.P.H. degree from Boston University School of Public Health, with a concentration in epidemiology and biostatistics, and a medical degree from the University of Medicine in Bucharest, Romania.
Himanshu Jain, M.S.(Pharm.), is a manager on the CNS/Ophthalmology Disorders team at Clarivate. He has authored content for ophthalmology (retinal / nonretinal) and psychiatry indications, including age-related macular degeneration, diabetic retinopathy / diabetic macular edema, glaucoma, uveitis, and schizophrenia. He has more than ten years of experience working in market research and consulting firms. He earned his master’s degree from the National Institute of Pharmacological Education and Research and holds an Executive Post-Graduate Diploma in international business from the Indian Institute of Foreign Trade.
Shefali Gulati, M.B.A., is an analyst on the CNS/Ophthalmology Disorders team at Clarivate. She is responsible for performing extensive secondary market research and analysis for major pharmaceutical markets. She has authored several CNS/Ophthalmology reports, including U.S. Treatment Algorithms, Unmet need, Special topics. Previously, Ms. Gulati was a knowledge management associate with ZS Associates, where she worked on multiple client projects pertaining to real-world claims data analysis, opportunity assessment, competitive landscape, pipeline analysis, and key product profiling. She holds an M.B.A. in pharmaceutical management from the National Institute of Pharmaceutical Education and Research and a bachelor’s degree in pharmacy from the Delhi Institute of Pharmaceutical Sciences and Research.